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Introduction
Breast cancer is a rather common malignancy in
women [1,2]. The evaluation of the biological aggres-
siveness of cancer cells might be used as prognostic
factor. Increasing number of surgery to treat breast
cancer inspired us to undertake some investigations in
order to get a deeper insight into etiology and patholo-
gy of this malignancy. Well known risk factors of
breast cancer are: race, age, sex, geographical environ-
ment, marital status, age at menarche, first pregnancy,
age of menopause, parity, past and present breast dis-
eases, exposure to radiation, diet and heredity. In 1999
The College of American Pathologists divided all
breast cancer prognostic factors into 3 groups. First
group includes factors of well-established clinical
value which are obligatory in clinical practice (tumor
dimensions, lymph node status, grade, histological
type, mitotic index and estrogen- and progesterone
receptor status). The second group consists of factors
whose significance was proved by a few authors
(HER-2, p53, Ki67, PCNA). Other factors of signifi-
cance not confirmed in clinical studies till now (DNA
ploidy, neoplastic angiogenesis, EGFR, TGF alpha,
bcl-2, pS2 and cathepsin D) are included in the third
group [3]. Some reports concerning the usefulness of
some molecular markers as risk and as prognostic fac-
tors in breast cancer came out recently [4-7]. Aim of
our study was to determine the correlation between the
expression of molecular markers (p53, c-erbB-2) and
clinical as well as histological picture in breast cancer
in females.
Materials and methods
Patients. Among 184 analyzed cases 148 patients (80% of all
cases) were in their 4th, 5th and 6th decade of life. In accordance
to TNM classification, 40 patients were T1, 140 patients were T2,
and 4 patients were classified as T3 (Table 1).
All the patients underwent ultrasound breast scan as well as
mammography before surgery. Only in 40 cases (21.7%) breast
cancer was detected by ultrasound, in 112 patients (60.9%) the
USG picture implied malignancy, and in 32 cases (17.4%) USG
revealed benign tumor. Mammography detected cancer merely in
36 cases (19.6%), but in 92 (50%) patients mammography implied
cancer, and in 56 cases (30.4%) benign changes was diagnosed by
mammography (Table 2).
Axillary nodes were not involved (N0) in 104 patients (56.5%),
and 80 (43.5%) patients histopathology revealed axillary lymph
nodes metastases (Table 1). 
All clinical data, including patient charts, operation notes,
histopathological data and immunohistochemical study on expres-
sion of c-erbB-2 and p53 in cancer tissue were meticulously ana-
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lyzed. Patients' charts and operation notes provided us with the
required information, including local clinical status, type of sur-
gery carried out, mammography and USG findings, clinical stage
of cancer according to the TNM classification and assessment con-
cerning histopathological type and grade of breast cancer. 
Tissue samples. Breast cancer tissue was obtained from 184
female subjects with primary breast cancer (clinical stage I and II),
who were treated in Department of Surgery, Wroc³aw, from 1992
to 2001; aged from 32 to 75 years (an average of 56.5 years).
According to hormonal status patients were divided into two
groups – premenopausal group (n=64) and postmenopausal group
(n=120). Each patient underwent mammectomy and axillary lym-
phadenectomy. 
Immunohistochemistry. Expression of molecular markers was
evaluated semi-quantitatively on paraffin slices, by the Department
of Pathological Anatomy.The material was immunohistochemical-
ly stained for c-erbB-2 (polyclonal antibody Dakopatts- Dania,
Code Nr. K-353) and p53 (monoclonal antibody, Dakopatts- Dania,
Code Nr. K-355) as described elsewhere and analyzed under light
microscopy, Olympus BX 50, with due consideration for location,
range and intensity of staining. 
Statistical analysis. For statistical analysis χ2 test was used.
Results
The reults of immunohistochemistry are presented in
Fig. 1 and 2. All our subjects (average age 56.5 yrs)
were diagnosed with local stage of breast cancer. In
accordance to the patients' age, the immunological
reactivity was seen as follows: highest percentage of
positive reaction against c-erbB-2 was seen in patients
in 5th and 8th decade of life, whereas highest per-
centage of positive reaction against p53 has been
detected in patients in 8th decade of life (Table 3). The
highest percent expression of protein p53 was found
among older patients as compared to expression of c-
erb-B2 (41-70 yrs vs. 71-80 yrs). Protooncogene c-
erbB-2 was detected in 54% of cases and anti-onco-
gene p53 in 33% of cases (Table 1).
As far as menopausal status of the patient is con-
cernedd, oncoprotein c-erbB-2 was detected in similar
percentages in both pre- and post- menopausal
patients. Considering tumor size, highest percentage of
c-erbB-2 positive cancer cells was detected in T2 and
T3, whereas anti-p53 in T1 tumor (Table 3).
Protooncogene c-erbB-2 was detected in 65% of
cases with no lymph nodes involvement (N0) and in
40% of cases with lymph nodes metastases (N1).
Antioncogene p53 was detected in 46.6% of (N0)
cases 20% of (N1) patients (Table 3).
In 156 of 184 cases (84.8%) ductal infiltrative
carcinoma or lobular infiltrative carcinoma was
diagnosed. Protooncogene c-erbB-2 was detected in
66.6% of ductal cancer cases, and in 55.5% of lobu-
lar cancer, whereas anti-oncogene p53 was detected
in 44.4% of ductal cancer and in 18.9% of lobular
cancer cases (Table 3).
Protooncogene c-erbB-2 was detected in cancer tis-
sue, in spite of the fact that USG reported a benign
tumor, but the incidence of c-erbB-2 positive cells was
significantly higher in group with breast cancer diag-
nosed by USG (p=0.035). The percentage of p53 pos-
itive cancer cells in tumors of malignancy implied by
USG was similar as compared with cancer diagnosed
in USG (p=0.01 vs. p=0.0003) (Table 4).
Protooncogene c-erbB-2 was detected in cancer
tissue inspite of its absence in mammography picture,
but was significantly higher in tumors diagnosed by
mammography as cancer. Statistically significant dif-
ference was noted in c-erbB-2 reactivity between
tumors diagnosed by mammography as benign as
compared to tumors of implied malignancy (p=0.02).
There was no difference between mammography
implied and mammography diagnosed tumors in p53
reactivity, but statistically significant difference was
revealed between tumors of benign mammography
appearance as compared with those of implied malig-
nancy (p=0.007). Similarly, statistically significant
difference in p53 reactivity was found between mam-
450 A.K. Agrawal et al.
©Polish Histochemical et Cytochemical Society
Folia Histochem Cytobiol. 2008:46(4): 450 (449-455) 
doi: 10.2478/v10042-008-0059-7
Table 1. Clinicopathological features reported in breast cancer
patients in our study.
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Table 2. USG and mammography results in relation to histopathological findings in breast cancer patients.
Table 3. c-erbB-2 and p53 overexpression in relation to clinicopathological features.
Table 4. Immunological reactivity of antibodies with regard to USG result.
Table 5. Immunological reactivity of antibodies with regard to mammography result.
mography benign and malignant tumors (p=0.042)
(Table 5).
Among 184 analyzed cases histopathology
revealed: invasive ductal carcinoma 100 cases (54%),
lobular invasive cancer carcinoma 30% of cases
(n=56), other types of breast cancer 16% of cases
(n=28).
Discussion
Protooncogene c-erb-B2 encodes glycoproteines
which are similar to epidermal growth factor receptor
(EGFR). It is considered that this product of c-erb-B2
might act as a receptor for different, still unknown
growth factors. Amplification or overexpression of c-
erb-B2 in female breast cancer was announced by
many authors, though the percentage of c-erbB-2
positive cells found in breast cancer tissue varies
among the published reports: 9% Barnes et al. [21],
10% Ali et al. [22], 11% Znou et al. [23], 17%,
Wright et al. [24], 26%, Lucroix et al. [25], 40%,
Berger et al. [26], 47% Guerin et al. [27] and 58%
Wang et al. [28]. In our study the overexpression of
c-erbB-2 was found in 54.3% cases of breast cancer.
According to us, discrepancy in the results presented,
by various authors may be due to the type of consol-
idation and the condition under which the material
was consolidated . 
Barnes et al. reported that consolidator change
strongly affects estimation of c-erb-B2 expression in
breast cancer [21]. Immunohistochemical staining for
c-erb-B2 and p53 depended on sample preparation
(paraffin embeded or snap frozen). The conformity of
detection of c-erb-B2 and p53 between paraffin-
embedded and snap frozen tissues cancer (breast and
gastric cancer) was confirmed in 50% cases. The out-
come of immnohistochemical staining may be affected
by consolidater and temperature, since both factors
destroy proteins structure. The same consolidater dif-
ferently affected the outcome of immunohistochemical
staining, depending on type of malignancy (breast
cancer vs. gastric cancer), which may result from dif-
ferent localization of c-erb-B2 and p53 and different
expression of c-erb-B2 and p53 in distinct cancers, and
additionally remains under the influence of the type of
immunochemistry technique employed [29,30].
Barnes et al. [21], Ali et al. [22] and Gruerin et al. [27]
described cytoplasmic and membrane type of c-erb-B2
expression. In our study mainly the cytoplasmic type
of reaction was revealed.
Protein p53 acts as a regulator of the cellular cycle
and is known as a negative activator of cells growth.
As DNA is destroyed the protein p53 can stop cellular
cycle in G phase. After DNA reparation is initiated,
p53 protein starts cellular cycle in phase S. Abnormal-
ities of gene p53 result in dysfunction of protein p53.
Beside its control function, p53 protein can also act as
a transcription factor for numerous oncogenes and
antioncogenes. 
Ten years ago, a new gene mdm2, was localized on
chromosome 12q. Three mdm2 gene products are con-
nected to normal protein p53, whereas the one without
N-terminated part of protein cannot be connect with
p53 [31,32]. 
The correlation between alteration of gene p53 and
breast cancer was observed in 1982. In 9% breast can-
cer patients, antibodies against the cellular protein
were found. Many authors described amplification or
overexpression p53 in breast cancer but their results
differed. Bartek et al. [33] and Thor et al. [34] and
Maru et al. [35] detected immunohistochemicaly p53
in paraffin skin embedded breast cancer samples in
20%, 26% and 50% cases respectively. Bartek report-
ed higher percentage of p53 positive breast cancers in
frozen tissues as compared to paraffin samples [33].
Accumulation of p53 tumor suppressor gene protein is
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Fig. 1. Immunological staining with anti-c-erbB-2 antybody. Fig. 2. Immunological staining with anti-p53 antybody.
generally elevated in 32% breast cancer. In our study
antioncogene p53 overexpression was found in 31.4%
of breast cancer cases. 
Antioncogene p53 was detected more often in pre-
menopausal period (Table 3) which is consistent with
literature data [13-15]. In postmenopausal patients,
antioncogene p53 was found in 50% of cases (Table 3),
which was higher than it is reported in world literature
(25-30%). As far as menopausal status of the patient is
concerned, oncoprotein c-erbB-2 was detected in sim-
ilar percentages in both pre- and post- menopausal
patients, similar to the published data. 
Considering tumor size, highest percentage of c-
erbB-2 positive cancer cells was detected in T2 and T3
groups; whereas anti-p53 in T1 tumor group (Table 3).
There is no unanimity among other authors who stud-
ied this correlation [16,17,18,19,20].
Correlation between the size of tumor and molec-
ular findings was confirmed by some authors
[36,37,38, 39]. Correlation between size of tumor and
alteration of p53protein was revealed. We found
accumulation of protein p53 in 37.5% T1 tumors and
in 26.9% in T2 tumors, but the increase of p53 accu-
mulation with increase of tumor size was not
observed. Our results are conformable with
Thompsen's results [40]. Some studies have
described a correlation between expression c-erb-B2
and tumor size. In our study expression of pro-
tooncogene c-erb-B2 increased with tumor size (37.5
% of T1 tumors vs. 57.7% of T2 tumors). 
Reports on correlations between USG and mam-
mography picture of breast cancer, and molecular
marker status is sparse in the literature published [41].
Among tumors diagnosed as malignant by ultrasonog-
raphy, 87.5% tumors was c-erb-B2 positive and 37%
was p53 positive. In cases with benign USG picture
the expression of c-erb-B2 was detected in 16.6%
cases and p53 was absent. Therefore our study clearly
indicates that comparison of USG and mammography
picture with molecular markers status may be impor-
tant for early diagnosis and prognosis.
The lymph node metastases reflects systemic dis-
semination of cancer and plays key role in tumor host
relationship. It was earlier thought that lymph nodes
metastases took place earlier than systemic dissemina-
tion of cancer, but Fisher showed that cancer cells
leave lymph nodes and enter the circulatory system
very fast [42]. Lymph node barrier, which stops the
spread of cancer cells may not be so efficient. Thus
absence of metastases in lymph nodes does not
exclude absence of secondary disease and distant
spread. The cancer cells may also disseminate through
connective tissue penetration into lymphatic vessel
[43]. 
The necrosis of cancer tissue seemed to be related
to higher histological grade of cancer and probably
with increased distant spread, but in not correlated
with expression of c-erb-B2 or p53 or status of axillary
lymph nodes.
In our study the incidence of p53 positive cases was
higher among (N+) patients as compared to (N-) ones.
Our results are consistent with Rosen's observations
[44]. Status of axillary lymph nodes did not affect c-
erb-B2 expression in cancer tissue. Vast majority of
reports described correlations between lymph node
status and molecular markers in breast cancer [45-47]
and merely few publications couldn't find relation-
ship between metastases to lymph node and p53 or c-
erb-B2 [48]. Carcinoma ductale infiltrans is the most
common type of breast cancer. It occurs in 45-84%
cases [11,12]. In our report it was found in 51.4%
patients (carcinoma ductale infiltrans in 66.6% cases
and multiple form in this cancer in 33.3% cases). In
patients in I and II stage of carcinoma ductale infil-
trans occurs more often (83.4%) than in patients in III
stage (16,6%). Clinical material included: carcinoma
ductale infiltrans (51.4%), carcinoma lobulare
(31.4%), carcinoma medullare (8.8%), carcinoma
adenoids cysticum. Only few of authors described
metastases in lymphnodes. Trojani et al. proved that
lymphnodes metastase in carcinoma ductale infiltrans
occurs in 57% cases and in carcinoma lobulare in
41.4% cases [49]. Lee and Terry described that dif-
ference in occurrence of metastases in carcinoma
ductale infiltrans and carcinoma lobulare is important
statistically compared with carcinoma medullare and
carcinoma adenoides cysticum (rare metastases) even
by size of tumour more than 4 cm [50]. A correlation
between molecular markers and malignant carcinoma
was found. 
Conclusions
In our study, expression of protooncogene c-erb-B2
was found in 66.6% cases of invasive ductal carcino-
ma and in 55.5% of invasive lobular carcinomas,
whereas expression of protein p53 was found in
44.4% and 18.1% of cases respectively. The percent-
age of c-erbB-2 positive cases increased along with
tumor dimensions. These findings are consistent with
literature data [5,51-55]. We observed correlation,
but not statistically important, between p53 expres-
sion and lymph node involvement. Marker p53 was
more often detected in breast cancer tissue from pre-
menopausal group. Both markers were detected more
frequently in cases diagnosed by USG or mammog-
raphy as malignant. Among all types of breast cancer,
ductal carcinomas cases were more often positive for
c-erbB-2 as well as p53. Above observations strong-
ly suggest that these molecular markers may be use-
ful in indicating the degree of biological aggressive-
ness of breast cancer.
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